Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–12. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. doi:10.1001/jama.2017.18718.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci. 2013;7:45. doi:10.3389/fncel.2013.00045.
   PubMed Web of Science ®Google Scholar
• Muller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017;18(1):234. doi:10.1186/s13059-017-1362-4.
   PubMedGoogle Scholar
• Annovazzi L, Mellai M, Bovio E, Mazzetti S, Pollo B, Schiffer D. Microglia immunophenotyping in gliomas. Oncol Lett. 2018;15(1):998–1006. doi:10.3892/ol.2017.7386.
   PubMed Web of Science ®Google Scholar
• Bienkowski M, Preusser M. Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: literature review. Curr Opin Neurol. 2015;28(6):647–658. doi:10.1097/WCO.0000000000000251.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang C, Maimela NR, Yang L, Zhang Z, Ping Y, Huang L, Zhang Y. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma. Oncoimmunology. 2019;8(7):1601478. doi:10.1080/2162402X.2019.1601478.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhao Q, Zhao S, Zhang P, Zhao H, Li Z, Du Y, Tian X, Lu J. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma. Cancer Med. 2019; doi:10.1002/cam4.2312.
   Web of Science ®Google Scholar
• Vauleon E, Tony A, Hamlat A, Etcheverry A, Chiforeanu DC, Menei P, Mosser J, Quillien V, Aubry M. Immune genes are associated with human glioblastoma pathology and patient survival. BMC Med Genomics. 2012;5(1):41. doi:10.1186/1755-8794-5-41.
   PubMedGoogle Scholar
• Arimappamagan A, Somasundaram K, Thennarasu K, Peddagangannagari S, Srinivasan H, Shailaja BC, Samuel C, Patric IRP, Shukla S, Thota B, et al. A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group. PLoS One. 2013;8(4):e62042. doi:10.1371/journal.pone.0062042.
   PubMed Web of Science ®Google Scholar
• Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, Wu A. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226–2234.
   PubMed Web of Science ®Google Scholar
• Moyes KW, Davis A, Hoglund V, Haberthur K, Lieberman NA, Kreuser SA, Deutsch GH, Franco S, Locke D, Carleton MO, et al. Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma. Oncoimmunology. 2018;7(11):e1507668. doi:10.1080/2162402X.2018.1507668.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213. doi:10.1056/NEJMoa020177.
   PubMed Web of Science ®Google Scholar
• Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PØ, Zimmer J, Chekenya M. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013;264(1–2):71–83. doi:10.1016/j.jneuroim.2013.08.013.
   PubMed Web of Science ®Google Scholar
• Yue Q, Zhang X, Ye HX, Wang Y, Du Z-G, Yao Y, Mao Y. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol. 2014;116(2):251–259. doi:10.1007/s11060-013-1314-0.
   PubMed Web of Science ®Google Scholar
• Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, et al. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017;23(2):6650–6660. doi:10.1158/1078-0432.CCR-17-0120.
   PubMedGoogle Scholar
• Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res. 2011;17(13):4296–4308. doi:10.1158/1078-0432.CCR-10-2557.
   PubMed Web of Science ®Google Scholar
• Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, Sampson JH, Mitchell DA. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. 2015;64(4):419–427. doi:10.1007/s00262-014-1651-7.
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211.
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi:10.1093/nar/gkn923.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, Sabedot T, Salama S, Murray B, Morozova O, Newton Y, Radenbaugh A, Pagnotta S, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550–563. doi:10.1016/j.cell.2015.12.028.
   PubMed Web of Science ®Google Scholar
• Aquilanti E, Miller J, Santagata S, Cahill DP, Brastianos PK. Updates in prognostic markers for gliomas. Neuro Oncol. 2018;20(suppl_7):vii17–vii26. doi:10.1093/neuonc/noy158.
   PubMedGoogle Scholar
• Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn D, Allison J, Merghoub T, Wolchok J. Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep. 2015;13(2):412–424. doi:10.1016/j.celrep.2015.08.077.
   PubMed Web of Science ®Google Scholar
• Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A. The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: a comprehensive meta-analysis. Front Oncol. 2018;8:27. doi:10.3389/fonc.2018.00027.
   PubMed Web of Science ®Google Scholar
• Cheng W, Ren XF, Zhang CB, Cai J, Liu Y, Han S, Wu A. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226–2234.
   PubMed Web of Science ®Google Scholar
• Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1(2):112–122. doi:10.1158/2326-6066.CIR-13-0028.
   PubMed Web of Science ®Google Scholar
• Bockmayr M, Klauschen F, Maire CL, Rutkowski S, Westphal M, Lamszus K, Schüller U, Mohme M. Immunological profiling of mutational and transcriptional subgroups in pediatric and adult high-grade gliomas. Cancer Immunol Res. 2019;7(9):1401–1411. doi:10.1158/2326-6066.CIR-18-0939.
   PubMed Web of Science ®Google Scholar
• Wang QH, Hu BL, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2017;32(1):42-+. doi:10.1016/j.ccell.2017.06.003.
   Web of Science ®Google Scholar
• Qian ZH, Li YM, Fan X, Zhang C, Wang Y, Jiang T, Liu X. Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. Oncoimmunology. 2018;7(6):e1434466. doi:10.1080/2162402X.2018.1434466.
   PubMed Web of Science ®Google Scholar
• Luoto S, Hermelo I, Vuorinen E, Hannus P, Kesseli J, Nykter M, Granberg K. TMIC-30. computational characterization of suppressive immune microenvironments in glioblastoma. Neuro-Oncology. 2018;20(suppl_6):262. doi:10.1093/neuonc/noy148.1089.
   Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncology. 2017;19(11):1460–1468. doi:10.1093/neuonc/nox054.
   PubMed Web of Science ®Google Scholar
• Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018;24(8):1192-+. doi:10.1038/s41591-018-0095-6.
   PubMed Web of Science ®Google Scholar
• Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127(4):1425–1437. doi:10.1172/JCI90644.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi:10.1056/NEJMoa043331.
   PubMed Web of Science ®Google Scholar
• Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS, Boviatsis EI, Barbatis C, Lea RW, Kalofoutis A, et al. Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol. 2009;70(6):391–397. doi:10.1016/j.humimm.2009.03.011.
   PubMed Web of Science ®Google Scholar
• Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, Martínez-Sales V. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neuro-Oncol. 2011;102(1):35–41. doi:10.1007/s11060-010-0290-x.
   PubMed Web of Science ®Google Scholar
• Shan Y, He X, Song W, Han D, Niu J, Wang J. Role of IL-6 in the invasiveness and prognosis of glioma. Int J Clin Exp Med. 2015;8:9114–9120.
   PubMed Web of Science ®Google Scholar
• Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. Jci Insight. 2016;1(2). doi:10.1172/jci.insight.85841.
   PubMed Web of Science ®Google Scholar
• Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, Drake C, O’Dea P, Bermingham N, Keohane C, et al. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neuro-Oncol. 2013;114(1):149–154. doi:10.1007/s11060-013-1164-9.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Lwin Z, Jiang HY, Templeton AJ, Zadeh G, Bernstein M, Chung C, Millar B-A, Laperriere N, Mason WP, et al. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression. J Neuro-Oncol. 2014;117(1):147–152. doi:10.1007/s11060-014-1366-9.
   PubMed Web of Science ®Google Scholar
• Mason M, Maurice C, McNamara MG, Tieu MT, Lwin Z, Millar B-A, Menard C, Laperriere N, Milosevic M, Atenafu EG, et al. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J Neuro-Oncol. 2017;132(3):463–471. doi:10.1007/s11060-017-2395-y.
   PubMed Web of Science ®Google Scholar
• Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Petersen-Baltussen HMJM, Ter Laan M, Wesseling P, Adema GJ. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of cd15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropath Exp Neur. 2015;74(5):390–400. doi:10.1097/NEN.0000000000000183.
   PubMed Web of Science ®Google Scholar
• Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Bossman SAJFH, Ter Laan M, Wesseling P, Adema GJ. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuro-Oncology. 2016;18(9):1253–1264. doi:10.1093/neuonc/now034.
   PubMed Web of Science ®Google Scholar
• Dubinski D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W, Wiendl H, Grauer OM. CD4 + T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology. 2016;18(6):807–818. doi:10.1093/neuonc/nov280.
   PubMed Web of Science ®Google Scholar
• Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, Mulkearns-Hubert EE, Sinyuk M, Hale JS, Onzi GR, et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018;3(21). doi:10.1172/jci.insight.122264.
   PubMed Web of Science ®Google Scholar
• Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9):1459–1468. doi:10.1038/s41591-018-0135-2.
   PubMed Web of Science ®Google Scholar
• Yeung YT, McDonald KL, Grewal T, Munoz L. Interleukins in glioblastoma pathophysiology: implications for therapy. Brit J Pharmacol. 2013;168(3):591–606. doi:10.1111/bph.12008.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. doi:10.1126/scitranslmed.aaa0984.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ, O’Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, et al. Rindopepimut with bevacizumab for patients with relapsed eGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase ii trial. Clin Cancer Res. 2020;26(7):1586–1594. doi:10.1158/1078-0432.CCR-18-1140.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373–1385. doi:10.1016/S1470-2045(17)30517-X.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-diaz de Cerio A, Tejada S, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019;25(3):470–476. doi:10.1038/s41591-018-0339-5.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–486. doi:10.1038/s41591-018-0337-7.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25(3):462–469. doi:10.1038/s41591-019-0349-y.
   PubMed Web of Science ®Google Scholar
• Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105–1111. doi:10.1093/bioinformatics/btp120.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–140. doi:10.1093/bioinformatics/btp616.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425. doi:10.1016/j.cels.2015.12.004.
   PubMed Web of Science ®Google Scholar